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ORIGINAL ARTICLE

Eﬀect of Bisphosphonates on Function and Mobility
Among Children With Osteogenesis Imperfecta:
A Systematic Review
Christopher S Constantino,1 Joseph J Krzak,2,3 Alissa V Fial,4 Karen M Kruger,1,2 Jacob R Rammer,1
Katarina Radmanovic,1 Peter A Smith,2 and Gerald F Harris1,2
1

Orthopedic and Rehabilitation Engineering Center, Marquette University and Medical College of Wisconsin, Milwaukee, WI, USA
Motion Analysis Laboratory, Shriners Hospital for Children, Chicago, IL, USA
3
Midwestern University, Physical Therapy Program, College of Health Sciences, Downers Grove, IL, USA
4
Research and Instructional Services, Raynor Memorial Libraries, Marquette University, Milwaukee, WI, USA
2

ABSTRACT
Osteogenesis imperfecta (OI) is a rare genetic connective tissue disorder that results in bone fragility and deformity. Management
is multidisciplinary. Although pharmacologic intervention with bisphosphonates (BP) is a standard of care for individuals with
severe OI, no consensus or reviews were found that focus on the eﬀects of bisphosphonates on function and mobility. PubMed,
CINAHL, Cochrane Library, Web of Science, and PEDro databases were searched for eligible articles for this review. Methodological
quality was assessed using the Cochrane Collaboration’s tool for risk of bias. Twenty‐six studies (801 children) were reviewed and
ﬁve showed a low risk of bias. Included studies showed signiﬁcant variability among clinical protocols for administering BP.
Randomized controlled trials did not demonstrate a signiﬁcant improvement in function and mobility with oral BP administration,
whereas nonrandomized open‐label uncontrolled studies demonstrated that oral and intravenous BP administration objectively
improved function and mobility. The most common outcome measure used by the studies included in this review was the Bleck
score. Eﬀect sizes (d = 0.28 to 4.5) varied among studies. This systematic review also summarized the apparent confounding
variables aﬀecting results of previous studies and provided suggestions to improve the quality of future studies. © 2019 The
Authors. JBMR Plus is published by Wiley Periodicals, Inc. on behalf of the American Society for Bone and Mineral Research.
KEY WORDS: OSTEOGENESIS IMPERFECTA; PAMIDRONATE; ALENDRONATE; ZOLEDRONIC ACID; OLPADRONATE; BLECK; PEDI

Introduction

O

steogenesis imperfecta (OI) is a rare, clinically heterogenous genetic connective tissue disorder marked by
low bone mass and increased bone fragility, resulting in increased susceptibility to fractures, deformities, and substantial growth abnormalities.(1) It has a reported incidence
of 1 per 10,000 to 20,000 births.(1–5) Early genetic studies on
OI documented that it is commonly caused by autosomal
dominant heterozygous mutations in one of the two genes
encoding type I collagen, COLIA1 and COLIA2, and recently,
mutations in other genes were documented to be involved
in its pathogenesis.(1–5) With variable clinical manifestations,
OI was initially classiﬁed into four types based on severity of
signs and symptoms using the Sillence classiﬁcation system:
types I and IV being mild and moderate, type II being lethal,
and type III being severe and progressively deforming.(6,7)
Recent studies have broadened the classiﬁcation of OI into

up to 19 types based on the genes involved.(5,8–10) The
classiﬁcation system by Sillence is still being used in a
modiﬁed fashion in current studies to stratify subject populations.(11–14) As a consequence of the physical impairments
brought about by OI, varying degrees of pain,(11,12) gait deviations,(13) and functional limitations(11–14) have also been
reported depending on the type and severity of OI. Lower
mobility scores,(11–13) limited performance of activities of
daily living,(12) and lower levels of participation in sports,
exercise, or physical function(11–13) have been reported in
individuals with OI. Despite limitations in functional activity,
studies show individuals with OI are still able to participate
and ambulate in the community but may show diﬃculty
keeping up with typically developing peers.(12–14)
Without a genetic cure for OI, management of the disease is
aimed at symptom reduction through a multidisciplinary
approach consisting of pharmacologic agents, orthopedic
interventions, physiotherapy, and rehabilitation.(15,16) Among
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pharmacologic interventions, bisphosphonates (BP) have been
considered standard of care for children with severe OI.(17–20)
BP can be administered orally or intravenously with varied efﬁcacy, and there are two types, both acting on osteoclasts (cells
that break down bone tissue) by disrupting their formation
(nitrogenous type BP) or initiating their apoptosis (non‐
nitrogenous type BP).(19,21)
Although BP therapy is widely used to treat OI, results on
improvements to function and mobility outcomes have been
variable.(22–24) Previously published systematic reviews and
meta‐analyses on BP focused on their eﬀects on increasing
bone mineral density and reducing fracture rate. The reports
mention function and mobility outcomes, but these were
considered secondary variables of interest.(16,25–27) To the
best of our knowledge, no consensus or systematic reviews
have been published to quantitatively describe how BP
therapy aﬀects measures of function and mobility among
individuals with OI.(12–14) Therefore, the purpose of the current work was to systematically review existing literature and
describe the eﬀects of BP therapy on improving measures of
function and mobility.

Materials and Methods
Inclusion criteria
Included studies were limited to populations involving male
and female children who have an established diagnosis of OI in
which at least one of the outcomes was the eﬀect of bisphosphonates on function and/or mobility using objective
outcome measures. Studies that included quality‐of‐life (QOL)
or well‐being as outcomes were included if objective parameters of function and mobility were included in the measuring
tools used in those studies. Randomized controlled trials (RCTs),
non‐randomized open‐label uncontrolled studies (NROs), NROs
with a historic control group, and retrospective studies were
included. Non‐randomized open‐label uncontrolled studies are
deﬁned as studies that are not randomized, all subjects
are given treatment (no control or placebo group), and both
the researchers and subjects are aware of the treatment administered (no blinding).

Search strategy
We searched the following electronic databases: PubMed, CINAHL (Cumulative Index to Nursing and Allied Health Professions), Cochrane Library (Cochrane Database of Systematic
Reviews, Cochrane Central Register of Controlled Trials), Web of
Science, and PEDro (Physiotherapy Evidence Database). The
initial search strategy was developed in PubMed, using a
combination of Medical Subject Terms (MeSH) and key words.
Once the initial search was determined, it was modiﬁed to ﬁt
the parameters of the other databases.

Selection of studies and data extraction
The two lead authors (CSC and JJK) screened the articles for
eligibility independently. In the event of disagreement, a third
reviewer (KMK) was included in the discussion until a consensus
was reached. A standardized data extraction form was created
during study selection and was used to compile relevant descriptive information and relevant data among the included
studies.
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Strategy for data synthesis
The reviewers provided a narrative synthesis of the ﬁndings
from the included studies, structured around OI population
type, route (oral or intravenous), dosage of BP administered,
and outcomes used to measure function and mobility. Based
on the anticipated heterogeneity of outcomes and data completeness, the reviewers provided a summary of intervention
eﬀects for each study (Table 1). Eﬀects of BP on measures of
function and mobility were calculated with standardized mean
diﬀerences on each outcome and eﬀect size when applicable.

Risk of bias (methodological quality) assessment
The two primary reviewers (CSC and JJK) assessed the methodological quality (risk of bias) of the articles independently
using the adapted version of the Cochrane Collaboration’s tool.
This tool reviews ﬁve domains, with 11 items. Each item was
scored “1” if the item was present in the article, and “0” if it was
not (Table 2). Studies fulﬁlling six or more items were regarded
as having a low risk of bias.(28,29) Disagreements were resolved
by including three reviewers (KMK, JRR, and KR) in the discussion until a consensus was reached. The strength of interrater agreement was measured using Cohen’s Ƙ coeﬃcient
(95% conﬁdence interval), with Ƙ = 0.41 to 0.60 indicating
moderate agreement, Ƙ = 0.61 to 0.80 indicating good agreement, and Ƙ ≥ 0.81 indicating very good agreement.(28,29)

Analysis of subgroups or subsets
Subgroup analyses were performed based on the route of
administration (oral or intravenous) of BP, function and mobility outcome measure used, and population.

Results
Figure 1 illustrates the article selection process. The search strategy
yielded 423 articles. Removing duplicates, the number was reduced to 210, and 173 were excluded based on title and abstract.
Full texts of the 37 remaining articles were screened, and one was
excluded because some participants were given growth hormone
in addition to pamidronate, and the results obtained from these
participants were not diﬀerentiated from those who received pamidronate only.(30) Two more were excluded because the main
intervention was not bisphosphonate administration.(31,32) Six
more were excluded because the outcomes used were not objective.(33–38) Two more were excluded because they were found to
be abstracts presented in proceedings.(39,40) A total of 26 full‐text
articles (801 male and female children) including four RCTs,(23,41–43)
17 NROs,(44,45,47,48,50–55,57,58,60–64) three NROs with a historic control
group,(49,56,59) and two retrospective studies(46,65) met the inclusion
criteria and were included. Population sizes (n) ranged from
n = 4(65) to n = 139.(42) Three NROs did not specify sex distribution.(48,51,63) OI types recruited by most of the studies were I,
III, and IV. Other NROs included participants with types V,(64) VI,(57)
VII,(65) and VIII.(53) Two NROs did not specify the OI type of their
population.(50,60) Two studies included participants with unclassiﬁed types in addition to types I, III, and IV.(42,54) One of the
retrospective studies recruited only females.(65) Bleck score (including its modiﬁed forms)(66,67) was the most common outcome
tool used in 19 (73%) studies, followed by the pediatric disability
inventory (PEDI),(68) used in six (23%) studies.
JBMR Plus
Plus (WOA)
JBMR
(WOA)

JBMR®1Plus
JBMR
Plus (WOA)

BP EFFECTS
ON FUNCTION
ANDAND
MOBILITY
IN CHILDREN
WITHWITH
OI 3
BP EFFECTS
ON FUNCTION
MOBILITY
IN CHILDREN
OIof

16
◼
3 ■

NRO

RCT

Ward
2011(42)

Adiyaman
2004(44)

RCT

Sakkers
2004(23)

RCT

RCT

Kok 2007(41)

Seikaly
2005(43)

Study
design

Author, year

Oral olpadronate,
10 mg/m2/d for
2 years

n = 34
treatment (n = 16)
(10 ± 3.1 years old),
placebo (n = 18)
(11 ± 3.9 years old),
16/18, I (n = 13),
III (n = 9), IV (n = 12)

PEDI
1000–1300 mg/d calcium, 800–
Oral alendronate pulverized
1200 mg/d phosphorus, and 400
into 5 mg (for patients
IU vitamin D
<30 kg) and 10 mg capsules
administered with at least 8
ounces of water, 30 minutes
before food intake while
maintaining an upright
position for at least 30
minutes after intake
600–800 mg Ca/d through diet and Bleck score
I.v. disodium pamidronate
supplements, 4000 IU vitamin
0.5 mg/kg/d diluted in
D/d
150–250 ml saline, over
2 hours for 3 consecutive
days spread over a year for
a total of 4 cycles

n = 20
3–15 years old, 11/9,
I (n = 2), III (n = 8),
IV (n = 10)

n=8
3.62–13.8 years old,
3/5, III (n = 5),
IV (n = 3)

PEDI

(Continues)

All subjects had a baseline Bleck
score of 0. After 1 year of
treatment, 5 subjects had a
score of 4, 2 had a score of 3,
and 1 had a score of 1.

Patients were treated for
12 months with alendronate
then crossed over to placebo
and vice‐versa.
17 of 20 ﬁnished the study.
No signiﬁcant diﬀerence in
mobility scores between
alendronate and placebo
(3.00 ± 1.84 versus 2.21 ± 1.00,
p = 0.980)

Of the baseline number of
participants, data from only 94
from the treatment group and
28 from the placebo group
were obtained due to dropout.
Mobility (PEDI): no signiﬁcant
diﬀerence from placebo

Modiﬁed Bleck score and mobility
(PEDI): no signiﬁcant diﬀerence
from placebo or compared with
baseline after 2 years of
treatment

Modiﬁed Bleck score
Pediatric disability
inventory (PEDI)

500 mg/m2/d calcium, 400 IU/d
cholecalciferol

Results

Health‐utility index‐ Ambulation (HUI) and athletic
performance domain (SPCC):
mark III (HUI),
no signiﬁcant diﬀerence from
Harter self‐
placebo or compared with
perception proﬁle
baseline after 2 years of treatment
for children (SPCC)
SPCC was used for participants
>6 years old

Outcome measure/s

500 mg/m2/d calcium, 400 IU/d
cholecalciferol

Other treatments

n = 139
Oral alendronate, 5 mg/d for Supplemental Ca and vitamin
D were added in quantities
treatment (n = 109)
patients <40 kg, 10 mg/d
to meet the dietary
(11 ± 3.6 years old),
for patients ≥40 kg for
reference intake if the dietary
placebo (n = 30) (11 ±
2 years
intake was inadequate
4.0 years old), 78/31, I
(n = 32), III (n = 39),
IV (n = 54)
unknown (n = 14)

Oral olpadronate,
10 mg/m2/d for
2 years

BP type, route, dosage, and
duration

n = 34
treatment (n = 16)
(10 ± 3.1 years old),
placebo (n = 18)
(11 ± 3.9 years old),
16/18, I (n = 13), III
(n = 9), IV (n = 12)

n, male/female, OI type

Table 1. Summary of Study Characteristics and Intervention Outcomes of Included Articles
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Study
design

NRO

NRO

NRO

Author, year

Falk 2003(45)

Alharbi
2008(47)

Astrom
2002(48)

Table 1. (Continued)

(Continues)

Ambulation improved in 21
subjects from a mean score of
8 to 6 on the Wilson scale.
Further improvement was
noted on 3 on their latest
follow‐up but the mean Wilson
scale score was still 6. 13 of 22
who could not ambulate
achieved walking with mean
improvement in Wilson scale
scores by 2. 15 improved in
Bleck scores from 0 to 2 within
2 years and at the latest follow‐
up. There was no change in the
Bleck score of the other 13
subjects. None deteriorated.

Wilson scale
Bleck score

n = 28
I.v. disodium pamidronate
18 subjects were given
0.6–18 years old,
10–40 mg/m2 over 5–8
1,25‐dihydroxycholecalciferol.
sex distribution not
hour monthly infusions for
stated, I (n = 6),
2–9 years. For the 1st
III (n = 10), IV (n = 12)
3 months, 10 mg/m2 was
given, then 20 mg/m2 for
the next 3 months, and
30 mg/m2. Dose was
increased to 40 mg/m2
for 5 children who
experienced bone pain.
Infusions were preceded
with hydration with
buﬀered glucose 25 mg/
mL (total dose 500 ml/m2
for 2–4 hours).

The overall mobility score
improved from 1.8 ± 1.7 to
2.9 ± 1.5 (p = 0.01). A signiﬁcant
1‐point improvement occurred
within the ﬁrst 2 years.

Bleck score

I.v. pamidronate disodium
Calcium 1 g/m2/d and
diluted in isotonic saline
1200 IU/d of vitamin D
over 3 hours for 3
consecutive days for
2–6 years. Patients 2–4
years old received 0.75 mg/
kg/d every 3 months; >4
years old received 1 mg/
kg/d every 4 months.

PEDI scores were inconclusive.
Two of the oldest patients
(14 and 7 years old) progressed
from being wheelchair‐
dependent to completely
ambulatory on OT evaluation.

Results

n = 27
2.3–12.3 years old,
14/13, I (n = 8), III
(n = 9), IV (n = 8),
V (n = 2)

Outcome measure/s
PEDI
Serial occupational
therapy (OT)
evaluations

Other treatments

Calcium carbonate supplements
I.v. pamidronate 1 mg/kg/d
when calcium intake was
dissolved in 5% dextrose,
insuﬃcient or ionized calcium
25% normal saline to
level below normal
achieve <0.12 mg/mL, over
3 hours for 3 consecutive
days every 3.8 months for
2 years. During day 1 of the
1st cycle only, dose was
0.5 mg/kg/d.

BP type, route, dosage, and
duration

n=6
1.8–14.7 years old, 3/3,
I (n = 1), III (n = 2),
IV (n = 3)

n, male/female, OI type
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n, male/female, OI type

NRO

NRO

Bajpai
2007(51)

Other treatments

I.v. disodium pamidronate
diluted in isotonic saline
1 mg/kg/d for
3 consecutive days every
3 months for 2 years
I.v. pamidronate diluted in
isotonic saline 1 mg/kg/d
over 3 hours for
3 consecutive days every
4 months for 2–3.8 years
until the age of 7.4 ± 4.1
years. During day 1 of the
1st cycle only, dose was
0.5 mg/kg/d.

n = 20
4.5 ± 4.2 years old
sex distribution not
stated, III (n = 13),
IV (n = 7)

Oral calcium carbonate
50 mg/kg/d

None mentioned

I.v. disodium pamidronate
None mentioned
10–30 mg/m2 monthly
infusions for 3–6 years
For the 1st 3 months,
10 mg/m2 was given, then
20 mg/m2 for the next
3 months, and 30 mg/m2.
Dose was increased
to 40 mg/m2 for 6 children
who experienced
bone pain.
Infusions were preceded with
hydration with buﬀered
glucose 25 mg/mL (total
dose 500 ml/m2 for
2–4 hours)

BP type, route, dosage, and
duration

n = 72
1–13 years old
40/32, type of OI not
speciﬁed

NRO with a n = 11
treatment (n = 11)
historic
(0.5 ± 3.3 years old,
control
historic controls
group
(n = 11)
(0.7 ± 0.44 years old),
10/12,
I (n = 5), III (n = 9),
IV (n = 8)

Study
design

Atta 2014(50)

Astrom
2007(49)

Author, year

Table 1. (Continued)

Bleck score

Bleck score

Wilson scale
Bleck score

Outcome measure/s

(Continues)

11 of 20 had ages where scores
were applicable at baseline, and
17 had scores applicable at the
end. Signiﬁcantly greater
proportion (88.2%) of children
had a functional score of 2 or
more (able to walk) at last follow‐
up compared with those at
initiation of treatment (45.4%).

Score improved from 0.94 ± 1.30
to 2.5 ± 1.02 (p < 0.001). Score
was 0 in 43 patients at baseline
compared with 4 (5.5%)
patients at study completion.

Both outcomes were not
applicable at baseline for 9
subjects because they were
under 6 months of age. After
1 year of treatment, mean score
on the Wilson scale was 6 and
mean Bleck score was 1. After
2 years, mean score on the
Wilson scale was 4 and mean
Bleck score was 2. On the latest
follow‐up, mean score on the
Wilson scale was 3, and mean
Bleck score was 3. Scores on
latest follow‐up were not
shown for the control group. It
was mentioned that 6 subjects
from the control groups lost
their previous mobility abilities.

Results
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Study
design

NRO

NRO

NRO

Author, year

Cho 2005(52)

Garganta
2018(53)

Glorieux
1998(54)

Table 1. (Continued)
Other treatments

Bleck score

800–1000 mg calcium per day
I.v. disodium pamidronate
through diet and
diluted in 250–500 mL
supplementation and 400 IU
isotonic saline 1.5–3.0 mg/
vitamin D per day
kg/infusion cycle over
4 hours for 3 consecutive
days every 6 months initially,
then every 4 months for 1.3
to 5 years. 1 had a dose of
3.75 mg/kg/infusion cycle
due to a slow response.

n = 30
3–16 years old
16/14, III (n = 9), IV
(n = 9), unclassiﬁed
type (n = 12)

Scale devised by the
researchers

Outcome measure/s

Pediatric Quality of
Life Inventory 4.0
Generic Core
Scales for Physical
Functioning
(PedsQL)

Oral alendronate 10 mg/d for Enough dietary calcium and
vitamin D were advised but not
patients >35 kg, 10 mg
provided to participants.
every other day for
patients weighing 20–35
kg, 10 mg every 3 days for
those <20 kg, given at least
1 hour before breakfast,
given for 2.1–5.1 years.

BP type, route, dosage, and
duration

n = 22
None mentioned
Pamidronate (n = 16) or
2–21 years old
zoledronic acid (n = 6) as per
14/8, I (n = 8), III (n = 7),
the chronic regimen of the
IV (n = 6), VIII (n = 1)
patients. I.v. pamidronate
diluted 1.1 mg/kg/d every 3
months for patients 2–3
years old, 1.5 mg/kg/d every
4 months for patients aged
>3. I.v. zoledronic acid 0.05
mg/kg/d every 6 months for
all ages. Mean length of time
between the 1st and 2nd
infusions was 6.9 months.

n = 16
6.3–15 years old
9/7, I (n = 7), III (n = 2),
IV (n = 7)

n, male/female, OI type

(Continues)

At baseline, 16 were conﬁned to a
bed or a wheelchair (score of 0
or 1). Six gained one grade, 5
gained two, and 1 gained three.
Four children progressed from
being wheelchair‐bound (grade
0 or 1) to walking
independently (score of 4). In
the other 14 children, no
change in grade was noticed.
Four of those 14 children had a
baseline score of 4.

Results are described in the
Discussion section.

7 patients had surgical or implant‐
related problems that may have
aﬀected their ambulatory/
mobility status. Of the
remaining 9, 5 were had
improvements on latest follow‐
up. Among 4 without
improvement, 1 with grade
5 started medication 2 years
before skeletal maturity,
another had leg length
discrepancy of 6 cm, 2 were
either grade 1 or 2 at the start
of medication use.

Results
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NRO

Study
design

BP type, route, dosage, and
duration
Other treatments

n = 16
800 mg/d calcium and 1000 IU/d
I.v. disodium pamidronate
1.2–1.9 years old
vitamin D at the beginning and
diluted in 150 mL isotonic
4/12, I (n = 2), III and IV
tapered later according to
saline 7–10 mg/kg/yr
(n = 14)
laboratory changes
monthly at the start, and
then was changed to 3–4
mg/kg/yr once a day with 4
cycles/yr because surgeons
noticed characteristics of
osteoporosis on the femur of
2 patients. Infusion was done
over 3 hours and patients
were rehydrated with 150
mL isotonic saline before
and after therapy. Duration
was 0.6–4.7 years (mean
2.50 ± 1.09 years).

n, male/female, OI type

I.v. pamidronate 0.25 mg/kg
None mentioned
Land 2006(56) NRO with a n = 59
on the 1st day, then 0.5 mg/
historic 0.5–15.7 years old,
kg on days 2 and 3, then 0.5
29/30,
control
mg/kg on all 3 days of
I (n = 18), III (n = 12),
group
subsequent cycles for
IV (n = 29)
patients <2 years old. 0.38
48 controls (matched for
mg/kg on the 1st day, then
age and OI type who
0.75 mg/kg on days 2 and 3
did not receive
of the 1st cycle and 0.75
pamidronate) were
mg/kg on all 3 days of
included.
subsequent cycles for those
No age‐matched
aged 2–3 years.
controls were found
Cycles were repeated every 3
for the other 11
months for patients ≤3 years
subjects who
old. 0.5 mg/kg on the 1st
received pamidronate
day, then 1 mg/kg on days
2 and 3 of the 1st cycle and
1 mg/kg on all 3 days of
subsequent cycles for those
>3 years old, with cycles
every 4 months. Each dose
was diluted in 0.9% saline
and administered for
4 hours. Treatment time was
3 years

Goksen
2006(55)

Author, year

Table 1. (Continued)

Modiﬁed Bleck score
(4‐point scale)
PEDI

Bleck score

Outcome measure/s

(Continues)

Assessment of functional skills
were not performed in children
who were younger than 0.6
years (n = 20).
Results are described in the
Discussion section.

14 of 16 completed 1 year of
treatment.
One patient was not included in
the evaluation for mobility
because she was under 2 years
of age.
Ambulation scores increased in 10
children: 4 gained four grades,
6 gained one. In 3 children, no
change was noticed. Before
therapy, 2 children were fully
functional.

Results

CONSTANTINO
ET AL.
■
◼ 8 8of 16CONSTANTINO
ET AL.

JBMR Plus
Plus (WOA)
JBMR
(WOA)

Study
design

NRO

NRO

Author, year

Land 2007(57)

Lowing
2007(58)

Table 1. (Continued)
BP type, route, dosage, and
duration
Other treatments

Outcome measure/s

n = 43
0.3–16 years old
21/22, I (n = 15), III
(n = 13), IV (n = 15)

None mentioned
After i.v. hydration with
buﬀered glucose 25 mg/
mL (500 mL/m2 for 2–4
hours), i.v. disodium
pamidronate was given
once a month with an
increasing dose from 10 to
30 mg/m2 over 4–8 hours
for 1 year.

The average level of ambulation
improved in OI type VI subjects
(baseline: 2.2 ± 1.2, after
treatment 2.9 ± 1.2) but was
lower than in the comparison
group (baseline: 3.3 ± 0.5, after
treatment: 3.8 ± 0.4) both
before and after treatment.
Gross motor function of the
subjects with OI type VI
assessed by the PEDI score
improved during pamidronate
treatment but was inferior
compared with the comparison
group.

Results

(Continues)

Improvement was found after 1
Functional and
year of treatment (p < 0.001).
caregiver
Mobility improved in 40 of 43
assistance scales of
children. 2 of the 3 who did not
the PEDI
improve had recurrent fractures
and intramedullary rodding
surgery. The third child had
maximum scores pretreatment.

I.v. pamidronate 0.25 mg/kg Calcium and vitamin D intake were Modiﬁed Bleck score
n = 10
on the 1st day, then 0.5
0.8–14.5 years old, 4/6,
maintained adequate according (4‐point scale)
PEDI
mg/kg on days 2 and 3,
VI (n = 10)
to the recommended daily
then 0.5 mg/kg on all
Other OI types matched
allowance.
3 days of subsequent
for age and criteria
cycles for patients <2
reﬂecting disease
years old.
severity for
0.38 mg/kg on the 1st day,
comparison type I
then 0.75 mg/kg on days
(n = 3), III (n = 1), IV
2 and 3 of the 1st cycle and
(n = 6), 0.5–13.9 years
0.75 mg/kg on all 3 days of
old, sex distribution
subsequent cycles for those
of the comparison
aged 2–3 years.
group not speciﬁed
Cycles were repeated every
3 months for patients
≤3 years old.
0.5 mg/kg on the 1st day,
then 1 mg/kg on days 2
and 3 of the 1st cycle and
1 mg/kg on all 3 days of
subsequent cycles for
those >3 years old, with
cycles every 4 months.
Each dose was diluted in
0.9% saline and administered
for 4 hours.
Treatment time was 3 years.

n, male/female, OI type

JBMR®1Plus
JBMR
Plus (WOA)
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n, male/female, OI type

NRO

NRO

Sanchez‐
Sanchez
2015(61)

Other treatments

(Continues)

Mean Bleck score before
treatment was 4 (range 1–9)
and was 6 (range 2–9) after
treatment (p = 0.001).

I.v. zoledronic acid 0.05 mg/ 4 received Ca, 4 received calcitriol, Modiﬁed Bleck score
(9‐point scale)
and 4 received both
kg over 1–2 hours every
6 months. Treatment doses
received by patients varied.

n = 14
6 months to 14 years
old, 8/6,
I (n = 6), III (n = 6), IV
(n = 2)

Both Bleck (2.3 ± 1.0 versus 0.8 ±
1.0 for controls) and PEDI gross
motor scores (36 ± 13 versus
24 ± 12 for controls) were
signiﬁcantly greater in the
pamidronate group (p < 0.001).

Modiﬁed Bleck score
(4‐point scale)
PEDI

Scores improved (p < 0.05) in all
but 3 children. These 3 had an
increase of 0 but did not have a
decrease of scores.

Results

Outcome measure/s

Bleck score
Ca through diet with
I.v. pamidronate bisodium
administration of 250–500 mg
1 mg/kg/d diluted in 250–
calcium and 200 IU vitamin D as
500 mL normal saline over
daily oral supplements
4 hours/3 consecutive days
every 4 months for 1 to
2 years. If response was
slow, dose was increased
to 2 mg/kg/d.

I.v. pamidronate, 3
Calcium intake was maintained
consecutive days/3 years.
adequate according to the
Patients received 0.25 mg/
recommended daily allowance.
kg on the 1st day of the
ﬁrst cycle, 0.5 mg/kg on
days 2 and 3 of the 1st
cycle, and 0.5 mg/kg daily
on all 3 days in subsequent
cycles. Cycles were
repeated every 2 months.
After the 2nd birthday,
treatment was continued
with cycles of 0.75 mg/kg
pamidronate daily on 3
successive days that were
repeated every 3 months.
>3.0 years of age,
pamidronate dose was
1 mg/kg daily for
3 days, and cycles were
repeated every 4 months.
Each dose was diluted in
0.9% saline solution and
administered slowly over
4 hours.

BP type, route, dosage, and
duration

n = 64
21 months to 10 years
old, 35/29
n = 53 had severe OI
(speciﬁc OI type not
speciﬁed)

NRO with a n = 58
historic treatment (n = 29)
(2 weeks to 23
control
months old), 15/14, I
group
(n = 13),
III (n = 9), IV (n = 12)
Historical untreated
control group
matched for age and
OI type (n = 29)

Study
design

Salehpour
2010(60)

Munns
2005(59)

Author, year

Table 1. (Continued)
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JBMR Plus
Plus (WOA)
JBMR
(WOA)

NRO

NRO

NRO

Zacharin
2002(63)

Zeitlin
2006(64)

Study
design

Vyskocil
2005(62)

Author, year

Table 1. (Continued)

During the study period,
ambulation score improved in 4
patients with OI type V and
remained unchanged in 1
patient. One patient was not
assessed because of young age.
The other 5 patients were
independent walkers (grade 4)
before pamidronate treatment
was started and remained so
during the observation interval.
In the control group, 4 patients
gained 1 to 3 grades, and in 2
patients no progress was noted.
The other 5 patients were
independent walkers before
and after 2 years of treatment.

I.v. pamidronate 0.25 mg/kg Calcium and vitamin D intake were Bleck score
n = 11
on the 1st day, then 0.5
1.8–15 years old
maintained adequate according
mg/kg on days 2 and 3,
5/6, V (n = 11)
to the recommended daily
then 0.5 mg/kg on all 3
Other OI types matched
allowance.
days of subsequent cycles
for age and criteria
for patients <2 years old.
reﬂecting disease
0.38 mg/kg on the 1st day
severity for comparison
then 0.75 mg/kg on days 2
type I (n = 1),
and 3 of the 1st cycle and
III (n = 1), IV (n = 9)
0.75 mg/kg on all 3 days of
2.2–15.9 years old
subsequent cycles for
Sex distribution of the
those aged 2–3 years.
comparison group
Cycles were repeated every
not stated
12 months for patients ≤3
years old.
0.5 mg/kg on the 1st day,
then 1 mg/kg on days
2 and 3 of the 1st cycle and
1 mg/kg on all 3 days of
subsequent cycles for
those >3 years old, with
cycles every 4 months.
Each dose was diluted in
0.9% saline administered
for 4 hours. Treatment time
was 2 years.

(Continues)

11 of 18 children completed
treatment.
Mobility increased in all patients.

None mentioned
I.v. disodium pamidronate
diluted in 200–500 mL
normal saline 1 mg/kg/d
over 2–3 hours for 3 days
every 4 months for 2 years

Bleck scores were 2.57 ± 1.15
pretreatment, 3.68 ± 0.95 after
3 years, p = 0.00001.

Results

Bleck score

Outcome measure/s

n = 18
1.4–14.5 years old, sex
and type (III and IV)
distribution not
speciﬁed

Other treatments
Bleck score

BP type, route, dosage, and
duration

n = 30
Ca, Mg, vit D, antacids,
Oral alendronate 5 mg/d
4–16 years old
tetracyclines, or sucralfate 2 hr
(patients aged 4–10 years)
16/14, I (n = 22), III (n =
after BP intake
and 10 mg/d (>10 years of
2), IV (n = 6)
age) for 3 years.

n, male/female, OI type

JBMR®1Plus
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R

R

Study
design

BP type, route, dosage, and
duration
Other treatments

n=7
13–18 years old, 6/1,
I (n = 7)

I.v. pamidronate disodium
800–1200 mg calcium and
0.75 mg/kg as a single dose
400 IU vitamin D
over 8 hours every 6
months in saline solution.
Number of doses of
treatment varied.

I.v. pamidronate 1 mg/kg/d
n=4
Calcium and vitamin D according
over 3 hours for 3
Type VII (n = 4) (3.9–12.7
to the recommended daily
consecutive days every
years old), other OI
allowance
4 months for 2–3.8 years
types for comparison
until the age of 7.4 ± 4.1
(I, III, IV) (n = 8)
years.
(0.5 ± 3.3 years)
During day 1 of the 1st cycle
3.9–12.7 years old
only, dose was 0.5 mg/kg/d.
All female

n, male/female, OI type

1
3
5
5
8
10
20

# of doses

Bleck score
improvement
8→9
9, no change
5→9
6→9
8→9
4→6
2→9

Number of doses of the treatment
received by each patient varied.

Mean Bleck score of the type VII
group was 3.25 ± 1.50 and was
3.50 ± 1.00 at the end. Mean
Bleck score of the group with
other types of OI was 3.50 ±
1.70 and was 3.75 ± 0.71.
PEDI scores did not reach
statistical signiﬁcance.

Modiﬁed Bleck score
(4‐point scale)
PEDI

Modiﬁed Bleck score

Results

Outcome measure/s

RCT = Randomized controlled trial; NRO = non‐randomized open‐label uncontrolled study; R = retrospective study; i.v. = intravenous administration.

Oztemur
2012(46)

Cheung
2009(65)

Author, year

Table 1. (Continued)

Table 2. Risk of Bias (Methodological Quality) Assessment

Risk of bias (methodological quality) assessment

Study

A B C D E F G H I J K Total

Adiyaman et al.(44)
Alharbi et al.(47)
Astrom et al. (2002)(48)
Astrom et al. (2007)(49)
Atta et al.(50)
Bajpai et al.(51)
Cheung et al.(65)
Cho et al.(52)
Falk et al.(45)
Garganta et al.(53)
Glorieux et al.(54)
Goksen et al.(55)
Kok et al.(41)
Land et al. (2006)(58)
Land et al. (2007)(57)
Lowing et al.(58)
Munns et al.(59)
Oztemur et al.(46)
Sakkers et al.(23)
Salehpour et al.(60)
Sanchez‐Sanchez
et al.(61)
Seikaly et al.(43)
Vyskocil et al.(62)
Ward et al.(42)
Zacharin et al.(63)
Zeitlin et al.(64)

0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
1
0
0

0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
1
0
0

0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
1
0
0

0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
1
0
0

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0

1
1
1
1
1
1
1
1
1
0
1
1
1
1
1
1
1
1
1
1
1

0
0
0
1
0
0
0
0
0
0
0
0
1
1
1
0
1
0
1
0
0

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
1
0
0

1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
0

1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1

1
0
1
1
1
0
1
0
0
1
0
0
1
1
0
1
1
0
1
0
0

4
3
4
5
4
3
4
3
3
3
3
3
9
5
4
4
6
3
11
3
2

Summary of scores of the adapted Cochrane Collaboration’s
tool is shown in Table 2. Interrater agreement was very good
(Ƙ = 0.94). Five studies scored ≥6 (low risk of bias).(23,41–43,59)

1
0
1
0
0

1
0
1
0
0

1
0
1
0
0

1
0
1
0
0

1
0
1
0
0

1
1
1
1
1

1
0
1
0
1

0
0
1
0
0

1
1
1
1
1

1
1
1
1
1

1
1
1
1
0

10
4
11
4
4

A = adequate randomization; B = concealed treatment allocation;
C = patients blinded; D = care providers blinded; E = outcome assessors blinded; F = drop‐out described and acceptable; G = participants analyzed in allocated groups; H = groups similar at
baseline; I = cointerventions avoided or similar; J = acceptable
compliance in all groups; K = similar timing of outcome assessment
in all groups.

Studies demonstrating a positive eﬀect of
bisphosphonates on function and mobility
Oral bisphosphonate administration
Two NROs administered oral alendronate on patients with OI types
I, III, and IV.(52,62) Cho and colleagues(52) measured function and
mobility in 16 patients using a scale the researchers devised
themselves. This scale was a 9‐point scale, with a highest possible
score of 1 (able to sprint and participate in contact sports) and a
lowest possible score of 9 (wheelchair‐ or bedridden; always requiring assistance from others, including self‐care activities). Seven
of their patients had surgical or implant‐related problems that may
have aﬀected their ambulatory/mobility status. Of the remaining
nine that did not have problems, ﬁve had improved scores on
latest follow‐up. Vyskocil and colleagues(62) used Bleck scores of 30
patients and reported signiﬁcant improvement in mobility (2.57 ±
1.15 to 3.68 ± 0.95 after 3 years; p = 0.00001) with an eﬀect size
(Cohen’s D, d) of 2.39.
Intravenous bisphosphonate administration
Most of the studies (69%) included in this review(44–51,54–60,63–65)
used intravenous pamidronate, administered at varying doses,
with durations ranging from 2 to 8 hours over 1 to 3 consecutive
days every 3 to 6 months, administered between 1 and 10 years
based on the participants’ needs. Table 1 shows detailed dosages
and treatment regimens used by each study.
Bleck score: Adiyaman and colleagues(44) found signiﬁcant
increases with a large eﬀect size among their population
(n = 8), all having Bleck scores of 0 at baseline, increasing to
a mean score of 3.38 ± 1.06 after 1 year of treatment (d = 4.50).
Oztemur and colleagues(46) administered treatment at varying
doses and all showed varying increases in scores (Table 1).
Alharbi and colleagues(47) showed improvement in 27

Fig. 1. Article selection process.
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participants from 1.8 ± 1.7 to 2.9 ± 1.5 (p = 0.01, d = 0.78). Atta
and colleagues(50) reported improved scores from 0.94 ± 1.30 to
2.5 ± 1.02 (p < 0.001, d = 1.03) among 72 patients. Bajpai and
colleagues(51) noted improvement from 1.36 ± 1.12 to
2.53 ± 1.18 (d = 1.23) among 17 participants. Astrom and colleagues(48) measured mobility using the Wilson scale (unpublished scale used in Sweden that has a highest score of
1 and lowest of 9) and the Bleck score. They reported improvements in both outcome measures (Bleck: 0.68 ± 1.22 to
1.57 ± 1.26; Wilson: 7.04 ± 2.50 to 4.86 ± 2.65), with eﬀect size
smaller on the Bleck scores (d = 0.28) compared with the Wilson
scale (d = 0.91).(48) Land and colleagues performed two studies
in 2006(56) and 2007.(57) In their earlier study, they reported
changes from baseline Bleck scores among 59 patients who
received 3 years of intravenous BP. Their results showed increased scores from baseline (0.84 ± 1.19 to 1.90 ± 1.25 after
3 years of treatment; p < 0.001, d = 0.58). In their later study,(57)
they compared Bleck scores among 10 patients with OI type VI
versus age‐ and disease severity‐matched patients with types I,
III, and IV. They found increased scores after treatment in both
groups but with lower scores among type VI patients compared
with those with types I, III, and IV (2.9 ± 1.2; p < 0.05, d = 1.42
versus 3.8 ± 0.4; p < 0.05, d = 7.29). Zeitlin and colleagues(64)
compared scores among 11 patients with OI type V versus age‐
and disease severity‐matched patients with types I, III, and IV,
and reported improved scores among type V patients 2.7 ± 1.7
at baseline to 3.3 ± 1.3 after treatment (p < 0.05, d = 0.83). The
scores of these patients were lower than the control group of
types I, III, and IV that had baseline and post‐treatment means
of 3 and 4, respectively. Cheung and colleagues(65) retrospectively reviewed 4 patients with OI type VII versus age‐ and
disease severity‐matched patients with types I, III, and IV and
reported non‐signiﬁcant increases in both groups. Glorieux and
colleagues(54) noted improvement in 16 of 30 participants.
Goksen and colleagues(55) noted improvement in 10 of 14
participants. Salehpour and colleagues(60) noted improvement
in 59 of 64 participants. Among the participants who had no
improvement in these three studies, their Bleck scores did not
change and none had reported lower Bleck scores after treatment. Zacharin and colleagues(63) also noted increased Bleck
scores among all their 18 participants. Means and individual
scores were not available in four studies.(54,55,60,63)
PEDI score: Lowing and colleagues(58) reported improvement
in the mobility domain of the functional and caregiver assistance
scales of PEDI after 1 year of treatment in 40 of 43 of their
participants (p < 0.001). Two of the three who did not improve
had recurrent periods with fractures and intramedullary rodding
surgery, whereas the other patient already had maximum scores
at baseline. The earlier study of Land and colleagues(56) reported
a signiﬁcant increase in PEDI scores after 3 years among the 59
patients with OI types I, III, and IV with similar changes from
baseline among the types (type I: 22.7 ± 18.7, type III: 24.6 ± 14.5,
type IV: 21.9 ± 15.8; analysis of variance: p = 0.59). In their later
study, they reported improvement in PEDI scores among OI type
VI patients, with their scores being lower than those with types I,
III, and IV.(57) Munns and colleagues(59) reported better scores
among those treated with i.v. BP (36 ± 13 versus 24 ± 12 for
controls, p < 0.001, d = 0.95). Cheung and colleagues(65) noted
non‐signiﬁcant increases in both groups.
Comparison with a historic untreated population: In another
study by Astrom and colleagues,(49) they compared Bleck and
Wilson scores of patients who received intravenous pamidronate
to scores of a historical untreated group. Better scores were found
JBMR®1Plus
JBMR
Plus (WOA)

among patients who received treatment on both Bleck (3.0 ± 0.77
versus 0.36 ± 0.67 for controls; p < 0.001, d = 3.63) and Wilson
(2.82 ± 2.09 versus 7.45 ± 1.51 for controls; p < 0.001, d = 2.55)
scores.(49) In their 2006 study, Land and colleagues(56) compared
historic data from 48 untreated patients and compared their
scores to 48 age‐matched patients who received treatment for
3 years. Their results showed signiﬁcantly higher Bleck scores
among the treatment group (2.1 ± 1.2) versus untreated
(1.0 ± 1.2), p = 0.001. The mobility domain of PEDI was also signiﬁcantly higher among the treatment group (76.3) versus untreated (58.3), p = 0.002. Munns and colleagues(59) showed
increased Bleck scores among 58 treated patients compared with
an age‐matched historical untreated control group (2.3 ± 1.0
versus 0.8 ± 1.0; p < 0.001, d = 0.75).
Intravenous zoledronic acid administration: Garganta and
colleagues(53) used both pamidronate (1.1 mg/kg/d every
3 months for patients 2 to 3 years old; 1.5 mg/kg/d every
4 months for patients aged >3 years old) and zoledronic acid
(0.05 mg/kg/d every 6 months) to treat 22 children with OI types
I, III, IV, and VIII and used the Pediatric Quality of Life Inventory
4.0 Generic Core Scales for Physical Functioning (PedsQL)(69) to
measure physical function. The choice of BP was based on what
regimen the patients were already taking at the start of the
study. Not all patients in this study were able to complete study
visits, and only 5 patients had data on all visits. These patients
had signiﬁcant changes in scores from the ﬁrst visit to the post‐
visit with mean PedsQL scores of 49.48 ± 25.49 before infusion
and 57.03 ± 25.29 after 4 weeks post‐infusion (p = 0.007,
d = 1.24). Physical function improved after the ﬁrst infusion and
diminished to pre‐infusion levels during the time of the next
infusion. Mean score was 46.88 ± 28.13 by the second infusion
(p = 0.008, d = 0.51). There were no signiﬁcant diﬀerences between patients treated with pamidronate and zoledronic acid
with respect to age, sex, or OI type. Sanchez‐Sanchez and colleagues(61) treated 14 children with OI types I, III, and IV with
zoledronic acid 0.05 mg/kg administered over 1 to 2 hours every
6 months with varying treatment durations. The study used the
modiﬁed Bleck score (9‐point scale) and noted improved mean
scores of 4 at pretreatment and 6 after treatment (p = 0.001).

Studies demonstrating no eﬀect on function and
mobility
All RCTs used oral BP including olpadronate 10 mg/m2/d(23,41)
and alendronate 5 mg/d (patients <40 kg) or 10 mg/d (patients
>40 kg).(42,44) Kok and colleagues(41) used the ambulation domain of the Health‐utility index‐mark III scale(70) and athletic
performance domain of the Harter self‐perception proﬁle for
children(71) for participants >6 years old to measure function
and mobility. Sakkers and colleagues(22) used both modiﬁed
Bleck scores and PEDI. The remaining two RCTs used PEDI.(42,43)
All RCTs reported no signiﬁcant diﬀerence between treatment
and placebo groups. In the 2006 study of Land and colleagues,(56) the self‐care domain of PEDI (measure of function)
was not signiﬁcant between the two groups. Falk and colleagues(45) also noted inconclusive PEDI scores in their study.

Discussion
The purpose of the current work was to systematically review
existing literature describing the eﬀect of BP therapy on
measures of function and mobility. The results of this current
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review show that children given intravenous BP have increased
mobility, as measured by Bleck scores, after treatment. Results
also showed that mobility scores were greater in patients with
OI type I, III, and IV compared with other types. Moreover,
based on the studies by Astrom and colleagues,(49) Land and
colleagues,(56) and Munns and colleagues,(59) improvements are
expected to be signiﬁcantly greater than one would expect
when compared with a historical untreated population.
All RCTs showed that oral BPs had no signiﬁcant eﬀect on
function and mobility scores between treatment and placebo
groups. In contrast, two NROs that used oral alendronate noted
improvements in mobility.(52,62) Cho and colleagues(52) used an
unpublished scale that the researchers devised themselves;
hence their ﬁndings cannot be compared with those from
other studies included in this review. Vyskocil and colleagues(62)
used the Bleck score, which is the scale most of the studies in
this review used, and it was also used by one of the RCTs
(Sakkers and colleagues(23)). Comparing these studies, population sizes were close (34 for Sakkers and colleagues; 30 for
Vyskocil and colleagues), but these studies diﬀered in terms of
treatment time (Sakkers and colleagues administered for
2 years; Vyskocil and colleagues for 3 years), age group (Sakkers
and colleagues = 10 ± 3.1 years old; Vyskocil and colleagues = 4
to 16 years old), and drug of choice (Sakkers and colleagues
used olpadronate; Vyskocil and colleagues used alendronate).
Between the two studies, Sakkers and colleagues has a lower
risk of bias, scoring 11/11 in the Cochrane Collaboration’s tool,
whereas Vyskocil and colleagues only scored 4/11. All studies
that administered BP intravenously were not randomized and
uncontrolled, and if control groups were included, they were
primarily limited to historical data. The paucity of RCTs in the
available literature can be explained by the fact that intravenous BP administration became a standard of care for the
management of severe OI before the RCTs were performed;
thus, including a placebo or untreated control group in a study
of severe OI is problematic. The three studies(49,56,59) that collected data from untreated groups obtained the data earlier
than the data from the treatment groups, and intravenous BP
may have not yet been used during that time. Relatively small
sample sizes among the included studies reﬂect the rarity of OI.
An improvement in mobility was consistent among all the
NROs that administered intravenous BP and used Bleck
scores (including its modiﬁed version) to measure
mobility.(44,47–51,54–57,59–61,63,64) Adiyaman and colleagues(44)
showed a very large eﬀect size (d = 4.5), which can be explained
by all his subjects starting with a score of 0 at baseline. In the
study by Oztemur and colleagues,(46) the varying dosages and
the small sample size reduced the power of the ﬁndings, but it
is still important to note that all patients either improved or
retained their baseline mobility scores and none had a decrease
after treatment. Alharbi and colleagues(47) reported a moderate
eﬀect size (d = 0.78), which can be explained by a number of
poor responders to treatment. The overall eﬀect to mobility,
however, was still an increase. The Wilson scale that Astrom
and colleagues used in both their studies is unpublished and
has not been veriﬁed or tested for reliability, but since both
studies also used Bleck, ﬁndings from both studies also contribute to the overall improved mobility scores found in this
review.(48,49) Moreover, it is consistent in all studies that treatment with i.v. BP does not decrease function or mobility scores.
Another consistent ﬁnding in this review is that baseline and
post‐treatment function and mobility scores are higher among
patients with types I, III, and IV compared with other types
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(types V,(64) VI,(57) VII(65)) as measured by both Bleck(55,57,64) and
PEDI(57,65) scores. Function and mobility scores measured by
PEDI were inconsistent. Falk and colleagues(45) noted inconclusive results and Cheung and colleagues(65) noted non‐signiﬁcant increases in scores, while four other studies(56–59)
reported improvement after i.v. BP administration. In the study
performed by Garganta and colleagues(53) using both i.v. pamidronate and zoledronic acid, increased function was noted
with the use of the PedsQL scales, but because this is the only
study that used this scale, no comparisons with other studies
can be made. The retrospective review by Cheung and colleagues,(65) which had a sample size of 4 and only included
females, was the only study to show non‐signiﬁcant increases
in Bleck scores after i.v. BP administration.
Limitations of this review include a high number of studies
(81%) with low methodologic quality. In addition, among the
studies that administered BP intravenously, only one study had
high methodologic quality.(59) This could be explained by the
Cochrane collaboration tool, which was used to appraise the
included studies regarding methodologic quality. As RCTs were
included in this review, an appraisal tool speciﬁc to RCTs was
employed. Because of this, any study that was not an RCT is
discredited in ﬁve of the 11 categories in the assessment tool.
Additionally, most of the studies included in this review scored
low on the appraisal tool for not having comparable groups at
baseline. This was not because they had diﬀerent baseline
groups, but because they had no control groups since these
were single‐group studies that tracked changes over time.
These were longitudinal studies that lacked comparison.
Another point, which was expected because of the rarity of
OI, has made the administration of BP, sample sizes, and follow‐
up periods very heterogeneous among the included studies.
Also, because of the wide ranges of age groups and diﬀerences
in demographic proﬁles and OI types, ﬁndings in the studies
may not have enough power to draw strong correlations.
Lastly, some studies included in this review may have been
underpowered for outcome measures related to function and
mobility. Most of the included studies were powered based on
a primary outcome of bone mineral density. Therefore, we are
uncertain if suﬃcient sample sizes were recruited in all studies
to identify an eﬀect of bisphosphonates on the chosen measures of function and mobility.
Hence, it is advised that our results be interpreted with caution
because of these limitations. We suggest that future studies be
conducted among comparable cohorts at baseline by ensuring
participants with similar ages, OI types, and functional status at
baseline to reduce confounding variables that may aﬀect the
outcome of these studies. Furthermore, these populations should
receive consistent treatment regimens and durations of BP administration in order to draw stronger conclusions regarding the
eﬀectiveness of BP administration on improving function and
mobility. Although intravenous BP is the standard of care and
RCTs involving placebo controls are not possible, controlled
studies that compare dosage regimens or combinations of BP
treatment with other modalities like physical therapy are also
suggested. It is suggested that better‐powered studies on the
eﬀect of BP on function and mobility among children with OI be
performed in the future.
This review, however, cannot answer which i.v. BP dosage
best improved mobility because of the heterogeneous studies
included, and future studies with more consistent dosages and
treatment times with bigger and more homogeneous samples
that measure mobility using the Bleck score are suggested.
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